Aspen Pharmacare has received Health Canada approval for Aspen-Semaglutide, its generic version of Novo Nordisk’s diabetes medicine Ozempic. Aspen, Africa’s largest pharmaceutical manufacturer, announced that its Canadian subsidiary had secured the regulatory authorisation. The medicine has been approved for the management of type 2 diabetes. The decision gives Aspen access to Canada’s expanding market for GLP-1 medicines. However, regulatory approval…